Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.

@article{Provencio2014ConsolidationTW,
  title={Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.},
  author={Mariano Provencio and Miguel {\'A} Cruz Mora and Jos{\'e} G{\'o}mez-Codina and Cristina Quero Blanco and Marta Llanos and Francisco Ram{\'o}n Garc{\'i}a-Arroyo and Luis de la Cruz and Josep Gum{\'a} Padr{\'o} and Juan Ram{\'o}n Delgado P{\'e}rez and Antonio S{\'a}nchez and Ruth {\'A}lvarez Cabellos and Antonio Rueda},
  journal={Leukemia & lymphoma},
  year={2014},
  volume={55 1},
  pages={51-5}
}
Relapse is the main cause of therapeutic failure in follicular lymphoma (FL). We set out to evaluate the role of consolidation with Yttrium-90 ibritumomab tiuxetan in patients with intermediate- and high-risk FL after four cycles of CHOP-R (cyclophosphamide, doxorubicin, vincristine, prednisone, rituximab) and two cycles of CHOP. Thirty patients were… CONTINUE READING